[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zura Bio Ltd (ZURA)

Zura Bio Ltd (ZURA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Zura Bio Spent Its Way Through Another Quarter With Nothing Left to Report But Runway

Zura Bio Ltd (ZURA) reports Q2 2026 earnings tomorrow, August 13, 2026, before market open. The central question: can this clinical-stage biopharmaceutical company narrow its losses as analysts project a -$0.19 EPS versus -$0.21 reported last quarter? With the stock trading at $5.78 and analysts maintaining an overwhelmingly bullish stance despite consistent earnings misses, investors will scrutinize whether ZURA's pipeline progress justifies the optimism heading into this release.

Zura Bio Ltd is a clinical-stage biopharmaceutical company focused on developing novel immunology therapies for autoimmune and inflammatory diseases. The company's lead programs target conditions with significant unmet medical needs, positioning it as a potential disruptor...

Fundamentals

See More
  • Market Capitalization, $K 548,412
  • Shares Outstanding, K 94,881
  • Annual Sales, $ 0 K
  • Annual Income, $ -99,350 K
  • EBIT $ -81 M
  • EBITDA $ -81 M
  • 60-Month Beta -0.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.43

Options Overview Details

View History
  • Implied Volatility 202.22% (+75.01%)
  • Historical Volatility 63.41%
  • IV Percentile 45%
  • IV Rank 23.87%
  • IV High 744.51% on 12/29/25
  • IV Low 32.16% on 09/08/25
  • Expected Move (DTE 8) 0.74 (13.13%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 128
  • Volume Avg (30-Day) 175
  • Put/Call OI Ratio 1.70
  • Today's Open Interest 6,926
  • Open Int (30-Day) 5,937
  • Expected Range 4.89 to 6.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.20
  • Number of Estimates 4
  • High Estimate $-0.19
  • Low Estimate $-0.22
  • Prior Year $-0.21
  • Growth Rate Est. (year over year) +4.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.94 +13.97%
on 07/15/26
6.01 -6.32%
on 08/07/26
+0.48 (+9.32%)
since 07/13/26
3-Month
3.25 +73.23%
on 06/05/26
6.01 -6.32%
on 08/07/26
+0.83 (+17.29%)
since 05/13/26
52-Week
1.57 +258.60%
on 08/14/25
7.44 -24.33%
on 03/10/26
+4.04 (+254.09%)
since 08/13/25

Most Recent Stories

More News
Zura Bio Spent Its Way Through Another Quarter With Nothing Left to Report But Runway

Barchart Research What to Expect from ZURA Earnings ZURA Generated August 12, 2026 Current Price $5.78 EPS Estimate $$-0.19 Consensus Rating Strong Buy Average Move 5.79% Zura Bio Spent Its Way Through...

ZURA : 5.63 (-2.60%)
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

TibuSHIELD enrollment complete, exceeding initial enrollment target with 247 participants randomized in HS; topline data expected Q4 2026 TibuSURE enrollment...

ZURA : 5.63 (-2.60%)
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

Tibulizumab is the first and only bispecific antibody targeting both BAFF and IL-17 in clinical development TibuSHIELD has completed enrollment, exceeding...

ZURA : 5.63 (-2.60%)
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with...

ZURA : 5.63 (-2.60%)
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and...

ZURA : 5.63 (-2.60%)
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

Continuing advancement of two Phase 2 studies evaluating tibulizumab in hidradenitis suppurativa (HS) (TibuSHIELD) and systemic sclerosis (SSc) (TibuSURE), with both trials on track to meet anticipated...

ZURA : 5.63 (-2.60%)
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with...

ZURA : 5.63 (-2.60%)
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates

Advancing two Phase 2 studies evaluating tibulizumab in hidradenitis suppurativa (HS) and systemic sclerosis (SSc) Topline data expected from the Phase...

ZURA : 5.63 (-2.60%)
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress

Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and...

ZURA : 5.63 (-2.60%)
Zura Bio to Participate in Upcoming Investor Conferences

Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients...

ZURA : 5.63 (-2.60%)

Business Summary

Zura Bio Limited is a clinical-stage biotechnology company advancing primary assets, including ZB-168 in Alopecia Areata and other inflammatory diseases and torudokimab in both chronic obstructive pulmonary disease and asthma. Zura Bio Limited, formerly known as JATT Acquisition Corp, is headquartered...

See More

Key Turning Points

3rd Resistance Point 6.05
2nd Resistance Point 5.94
1st Resistance Point 5.78
Last Price 5.63
1st Support Level 5.51
2nd Support Level 5.40
3rd Support Level 5.24

See More

52-Week High 7.44
Last Price 5.63
Fibonacci 61.8% 5.20
Fibonacci 50% 4.51
Fibonacci 38.2% 3.81
52-Week Low 1.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.